{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:58Z","timestamp":1794047458891,"version":"4.8.0"},"reference-count":36,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T00:00:00Z","timestamp":1701302400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Examination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations with survival outcomes) among newly diagnosed MM patients of non-Hispanic (NH) Black\/African American (AA) and NH White race\/ethnicity in the US. We included patients from the nationwide Flatiron Health electronic health record-derived de-identified database who initiated first line of therapy (LOT) for MM between January 1, 2016 and March 31, 2022. Of 4,614 patients in our study cohort, 23.3% were NH Black\/AA. Non-Hispanic Black\/AA patients were younger than NH White patients at diagnosis (median 68 vs. 71 years) and more likely to be female (53.4% vs. 43.5%). Rates of high-risk cytogenetics and 1q21+ were similar between races\/ethnicities. The most common primary regimen used was lenalidomide-bortezomib-dexamethasone (50.1% of NH Black\/AA and 48.1% of NH White patients). Receipt of stem cell transplantation during first LOT was less common among NH Black\/AA (16.5%) than NH White (21.9%) patients. Unadjusted RW progression-free survival (rwPFS) and overall survival (rwOS) were similar between races\/ethnicities. After multivariable adjustment, NH Black\/AA race\/ethnicity was associated with slightly inferior rwPFS (hazard ratio [HR]=1.13; 95% confidence interval [CI]: 1.01-1.27). The difference in rwOS (HR=1.12; 95% CI: 0.98-1.28) was not statistically significant. In general, associations between risk factors for rwPFS and rwOS were consistent between races\/ethnicities. Findings from this analysis help to inform clinicians about the impact of race\/ethnicity on MM treatment paradigms and outcomes in the US.<\/jats:p>","DOI":"10.3324\/haematol.2023.282788","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T03:40:40Z","timestamp":1701315640000},"page":"1882-1892","source":"Crossref","is-referenced-by-count":3,"title":["Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black\/African American and non- Hispanic White race\/ethnicity in the United States"],"prefix":"10.3324","volume":"109","author":[{"given":"Tondre","family":"Buck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique A.","family":"Hartley-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Efebera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter P.","family":"Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Salinardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Rice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"key":"62196","unstructured":"Cancer Stat Facts: Myeloma. National Institutes of Health Surveillance, Epidemiology, and End Results Program. 2022."},{"key":"62197","unstructured":"National Cancer Institute. Myeloma: People Alive with Cancer (U.S. Prevalence) on January 1. 2020."},{"key":"62198","unstructured":"American Cancer Society. Cancer facts and figures for African Americans 2022-2024. 2022."},{"key":"62199","doi-asserted-by":"crossref","unstructured":"Rosenberg PS, Barker KA, Anderson WF. Future distribution of multiple myeloma in the United States by sex, age, and race\/ ethnicity. Blood. 2015; 125(2):410-412.","DOI":"10.1182\/blood-2014-10-609461"},{"key":"62200","doi-asserted-by":"crossref","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017; 1(4):282-287.","DOI":"10.1182\/bloodadvances.2016002493"},{"key":"62201","doi-asserted-by":"crossref","unstructured":"Waxman AJ, Mink PJ, Devesa SS. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood. 2010; 116(25):5501-5506.","DOI":"10.1182\/blood-2010-07-298760"},{"key":"62202","doi-asserted-by":"crossref","unstructured":"Ahmed N, Shahzad M, Shippey E. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022; 28(7):358-364.","DOI":"10.1016\/j.jtct.2022.04.008"},{"key":"62203","doi-asserted-by":"crossref","unstructured":"Alqazaqi R, Schinke C, Thanendrarajan S. Geographic and racial disparities in access to chimeric antigen receptor-T cells and bispecific antibodies trials for multiple myeloma. JAMA Netw Open. 2022; 5(8):e2228877.","DOI":"10.1001\/jamanetworkopen.2022.28877"},{"key":"62204","doi-asserted-by":"crossref","unstructured":"Emole J, Lawal O, Lupak O, Dias A, Shune L, Yusuf K. Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States. Cancer Med. 2022; 11(23):4440-4448.","DOI":"10.1002\/cam4.4797"},{"key":"62205","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Parikh K, Abouzaid S. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019; 3(20):2986-2994.","DOI":"10.1182\/bloodadvances.2019000308"},{"key":"62206","doi-asserted-by":"crossref","unstructured":"Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020; 10(8):80.","DOI":"10.1038\/s41408-020-00347-6"},{"key":"62207","doi-asserted-by":"crossref","unstructured":"Dong J, Garacci Z, Buradagunta CS. Black patients with multiple myeloma have better survival than White patients when treated equally: a matched cohort study. Blood Cancer J. 2022; 12(2):34.","DOI":"10.1038\/s41408-022-00633-5"},{"key":"62208","doi-asserted-by":"crossref","unstructured":"Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. 2017; 123(9):1590-1596.","DOI":"10.1002\/cncr.30526"},{"key":"62209","doi-asserted-by":"crossref","unstructured":"Greenberg AJ, Philip S, Paner A. Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer J. 2015; 5(1)","DOI":"10.1038\/bcj.2014.91"},{"key":"62210","doi-asserted-by":"crossref","unstructured":"Kazandjian D, Hill E, Hultcrantz M. Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. Blood Cancer J. 2019; 9(2):15.","DOI":"10.1038\/s41408-019-0177-9"},{"key":"62211","doi-asserted-by":"crossref","unstructured":"Fillmore NR, Yellapragada SV, Ifeorah C. With equal access, African American patients have superior survival compared to White patients with multiple myeloma: a VA study. Blood. 2019; 133(24):2615-2618.","DOI":"10.1182\/blood.2019000406"},{"key":"62212","doi-asserted-by":"crossref","unstructured":"Maignan K, Fashoyin-Aje LA, Torres AZ. Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer J. 2022; 12(4):65.","DOI":"10.1038\/s41408-022-00665-x"},{"key":"62213","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2022."},{"key":"62214","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR. MedRxiv. 2022."},{"key":"62215","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Aldoss IT, Yang D. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012; 158(1):91-98.","DOI":"10.1111\/j.1365-2141.2012.09124.x"},{"key":"62216","doi-asserted-by":"crossref","unstructured":"Ailawadhi S, Jagannath S, Lee HC. Association between race and treatment patterns and survival outcomes in multiple myeloma: a Connect MM Registry analysis. Cancer. 2020; 126(19):4332-4340.","DOI":"10.1002\/cncr.33089"},{"key":"62217","unstructured":"Blakeslee L, Caplan Z, Meyer JA, Rabe MA, Roberts AW. Age and sex composition: 2020. US Census Bureau. 2023."},{"key":"62218","unstructured":"Race and Ethnicity in the United States: 2010 census and 2020 census. US Census Bureau. 2023."},{"key":"62219","doi-asserted-by":"crossref","unstructured":"Calip GS, Ascha MS, Wang X. Racial and age-related differences in impacts of high-risk cytogenetic abnormalities on survival in multiple myeloma in a nationwide electronic health record-derived database. Blood. 2021; 138(Suppl 1):4121.","DOI":"10.1182\/blood-2021-152774"},{"key":"62220","doi-asserted-by":"crossref","unstructured":"Richardson PG, Jacobus SJ, Weller EA. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022; 387(2):132-147.","DOI":"10.1056\/NEJMoa2204925"},{"key":"62221","doi-asserted-by":"crossref","unstructured":"Atrash S, Thompson-Leduc P, Tai MH. Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study. Clin Lymphoma Myeloma Leuk. 2022; 22(8):e708-e715.","DOI":"10.1016\/j.clml.2022.03.014"},{"key":"62222","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar S, Plesner T. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019; 380(22):2104-2115.","DOI":"10.1056\/NEJMoa1817249"},{"key":"62223","doi-asserted-by":"crossref","unstructured":"Mateos MV, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018; 378(6):518-528.","DOI":"10.1056\/NEJMoa1714678"},{"key":"62224","doi-asserted-by":"crossref","unstructured":"Bergin K, Wellard C, Augustson B. Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplant. 2021; 56(10):2533-2543.","DOI":"10.1038\/s41409-021-01308-8"},{"key":"62225","doi-asserted-by":"crossref","unstructured":"Kumar L, Hussain MM, Chethan R. Multiple myeloma: impact of time to transplant on the outcome. Clin Lymphoma Myeloma Leuk. 2022; 22(9):e826-e835.","DOI":"10.1016\/j.clml.2022.04.020"},{"key":"62226","doi-asserted-by":"crossref","unstructured":"Medhekar R, Ran T, Fu AZ, Patel S, Kaila S. Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received bortezomib in combination with lenalidomide and dexamethasone as first line of therapy in the United States. BMC Cancer. 2022; 22(1):901.","DOI":"10.1186\/s12885-022-09980-9"},{"key":"62227","doi-asserted-by":"crossref","unstructured":"Fillmore NR, Cirstea D, Munjuluri A. Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study. Blood Adv. 2021; 5(18):3511-3514.","DOI":"10.1182\/bloodadvances.2020004001"},{"key":"62228","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol. 2022; 40(29):3406-3418.","DOI":"10.1200\/JCO.22.02228"},{"key":"62229","doi-asserted-by":"crossref","unstructured":"Chng WJ, Dispenzieri A, Chim CS. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014; 28(2):269-277.","DOI":"10.1038\/leu.2013.247"},{"key":"62230","doi-asserted-by":"crossref","unstructured":"Ellington TD, Henley SJ, Wilson RJ, Wu M, Richardson LC. Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016. Cancer Med. 2021; 10(1):386-395.","DOI":"10.1002\/cam4.3444"},{"key":"62231","doi-asserted-by":"crossref","unstructured":"Richardson PG, San Miguel JF, Moreau P. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018; 8(11):109.","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282788\/76380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282788\/77068","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11357\/76380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:20Z","timestamp":1794045920000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282788","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}